Abstract
Abstract The malaria drug artemisinin has previously been identified as a potent anti-lymphoma drug to treat B-cell lymphoma and myeloid leukemia, but treatment of T lymphoma is rarely reported. In this study, we found that artemisinin can not only cause ferroptosis by up-regulating ROS levels and increasing misfolded protein in T cell lymphoma via down-regulating ERK pathway, but also reduce the accumulation of MDSCs, relieve the immunosuppressive effect of MDSCs on effector T cells, induce anti-tumor immune reactivation, and inhibit tumor growth in tumor bearing mice. This work was supported by the National Key R&D Program of China (2019YFA0906100), National Natural Science Foundation of China (Grants 82071772, 81501356 and 81373112), Key-Area Research and Development Program of Guangdong Province (2019B020201014), the Shenzhen Basic Science Research Project(Grants JCYJ20190807161419228, JCYJ20170818155135838, JCYJ20170818164619194, and JCYJ201 70413153158716), China Postdoctoral Science Foundation (2019M660220), Basic and Applied Basic Research Foundation of Guangdong Province (2019A1515110359), Nanshan pilot team project (LHTD20160004), Start-up funding (CYZZ20180307154657923).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
